Press Release

CG Oncology Announces Upsized $437 Million IPO

January 29, 2024

New York – January 29, 2024 – Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led the Cooley team advising the underwriters.

Morgan Stanley, Goldman Sachs & Co. and Cantor acted as joint book-running managers for the offering. LifeSci Capital acted as co-manager for the offering. CG Oncology offered a total of 23,000,000 shares of common stock, priced at $19 per share, which includes the exercise in full of the underwriters’ option to purchase 3,000,000 additional shares of common stock. The listing began trading on the Nasdaq Global Select Market on January 25, 2024, under the symbol CGON.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.